<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!-- Created with Liquid XML Studio - FREE Community Edition 7.1.6.1440 (http://www.liquid-technologies.com) -->
<ns2:studies xmlns:ns2="http://webservice.caaers.cabig.nci.nih.gov">
	<ns2:study>
		<shortTitle>Phase II Trial of Albumin-Bound Paclitaxel in Combination with Gemcitabine and Bevacizumab in Patients with Metastatic Breast Cancer</shortTitle>
		<longTitle>Phase II Trial of Albumin-Bound Paclitaxel in Combination with Gemcitabine and Bevacizumab in Patients with Metastatic Breast Cancer</longTitle>
		<description>Phase II Trial of Albumin-Bound Paclitaxel in Combination with Gemcitabine and Bevacizumab in Patients with Metastatic Breast Cancer</description>
		<phaseCode>Phase II Trial</phaseCode>
		<status>Active - Trial is open to accrual</status>
		<multiInstitutionIndicator>true</multiInstitutionIndicator>
		<adeersReporting>false</adeersReporting>
		<otherMeddra>MedDRA v9</otherMeddra>
		<ns2:aeTerminology>
			<ns2:ctcVersion>
				<name>3</name>
			</ns2:ctcVersion>
		</ns2:aeTerminology>
		<ns2:diseaseTerminology>
			<diseaseCodeTerm>CTEP</diseaseCodeTerm>
		</ns2:diseaseTerminology>
		<drugAdministrationTherapyType>true</drugAdministrationTherapyType>
		<deviceTherapyType>false</deviceTherapyType>
		<radiationTherapyType>false</radiationTherapyType>
		<surgeryTherapyType>false</surgeryTherapyType>
		<behavioralTherapyType>false</behavioralTherapyType>
		<biologicalTherapyType>false</biologicalTherapyType>
		<geneticTherapyType>false</geneticTherapyType>
		<dietarySupplementTherapyType>false</dietarySupplementTherapyType>
		<otherTherapyType>false</otherTherapyType>
		<reportTypeCaaersXML>true</reportTypeCaaersXML>
		<reportTypeAdeersPDF>true</reportTypeAdeersPDF>
		<reportTypeMedwatchPDF>true</reportTypeMedwatchPDF>
		<reportTypeDCPSAEForm>false</reportTypeDCPSAEForm>
		<reportTypeCIOMSForm>false</reportTypeCIOMSForm>
		<reportTypeCIOMSAEForm>false</reportTypeCIOMSAEForm>
		<fundingSponsor>
			<organizationAssignedIdentifier>
				<value>N0735</value>
			</organizationAssignedIdentifier>
			<ns2:studyFundingSponsor>
				<ns2:organization>
					<name>Cancer Therapy Evaluation Program</name>
					<nciInstituteCode>CTEP</nciInstituteCode>
				</ns2:organization>
			</ns2:studyFundingSponsor>
		</fundingSponsor>
		<coordinatingCenter>
			<organizationAssignedIdentifier>
				<value>N0735</value>
			</organizationAssignedIdentifier>
			<ns2:studyCoordinatingCenter>
				<ns2:organization>
					<name>North Central Cancer Treatment Group</name>
					<nciInstituteCode>NCCTG</nciInstituteCode>
				</ns2:organization>
			</ns2:studyCoordinatingCenter>
		</coordinatingCenter>
		<studyOrganizations>
			<ns2:studySite>
				<ns2:organization>
					<name>Mayo Clinic Rochester</name>
					<nciInstituteCode>MN026</nciInstituteCode>
				</ns2:organization>
				<studyPersonnels>
					<ns2:studyPersonnel>
						<roleCode>caaers_participant_cd</roleCode>
						<startDate>2009-08-31</startDate>
						<endDate>2011-02-01</endDate>
						<ns2:researchStaff>
							<firstName>mayo</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>mayo-rs1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_ae_cd</roleCode>
						<startDate>2009-08-31</startDate>
						<ns2:researchStaff>
							<firstName>mayo</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>mayo-rs1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_central_office_sae_cd</roleCode>
						<startDate>2009-11-11</startDate>
						<ns2:researchStaff>
							<firstName>mayo</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>mayo-rs1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_site_cd</roleCode>
						<startDate>2009-12-15</startDate>
						<ns2:researchStaff>
							<firstName>mayo</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>mayo-rs1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_participant_cd</roleCode>
						<startDate>2011-01-26</startDate>
						<endDate>2011-03-26</endDate>
						<ns2:researchStaff>
							<firstName>Smoke</firstName>
							<lastName>Tester1</lastName>
							<nciIdentifier>SMOKE_RS_1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_participant_cd</roleCode>
						<startDate>2010-02-26</startDate>
						<endDate>2011-03-01</endDate>
						<ns2:researchStaff>
							<firstName>research</firstName>
							<lastName>staff-ws</lastName>
							<nciIdentifier>ws-rs1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_site_cd</roleCode>
						<startDate>2010-02-26</startDate>
						<endDate>2011-03-02</endDate>
						<ns2:researchStaff>
							<firstName>research</firstName>
							<lastName>staff-ws</lastName>
							<nciIdentifier>ws-rs1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
				</studyPersonnels>
			</ns2:studySite>
			<ns2:studySite>
				<ns2:organization>
					<name>North Central Cancer Treatment Group</name>
					<nciInstituteCode>NCCTG</nciInstituteCode>
				</ns2:organization>
				<startDate>2009-10-01</startDate>
				<endDate>2011-10-01</endDate>
			</ns2:studySite>
		</studyOrganizations>
		<identifiers />
		<studyAgents>
			<ns2:studyAgent>
				<ns2:agent>
					<name>Bevacizumab (rhuMAb VEGF)</name>
				</ns2:agent>
				<indType>OTHER</indType>
				<partOfLeadIND>false</partOfLeadIND>
				<studyAgentINDAssociations>
					<ns2:studyAgentINDAssociation>
						<ns2:investigationalNewDrug>
							<indNumber>-111</indNumber>
						</ns2:investigationalNewDrug>
					</ns2:studyAgentINDAssociation>
				</studyAgentINDAssociations>
			</ns2:studyAgent>
			<ns2:studyAgent>
				<ns2:agent>
					<name>Gemcitabine hydrochloride</name>
				</ns2:agent>
				<indType>NA_COMMERCIAL</indType>
			</ns2:studyAgent>
			<ns2:studyAgent>
				<ns2:agent>
					<name>Paclitaxel protein-bound particles (albumin-bound) (Abraxane)</name>
				</ns2:agent>
				<indType>OTHER</indType>
				<partOfLeadIND>true</partOfLeadIND>
				<studyAgentINDAssociations>
					<ns2:studyAgentINDAssociation>
						<ns2:investigationalNewDrug>
							<indNumber>-111</indNumber>
						</ns2:investigationalNewDrug>
					</ns2:studyAgentINDAssociation>
				</studyAgentINDAssociations>
			</ns2:studyAgent>
		</studyAgents>
		<ctepStudyDiseases>
			<ns2:ctepStudyDisease>
				<ns2:diseaseTerm>
					<term>Invasive breast carcinoma</term>
				</ns2:diseaseTerm>
				<leadDisease>true</leadDisease>
			</ns2:ctepStudyDisease>
			<ns2:ctepStudyDisease>
				<ns2:diseaseTerm>
					<term>Hematopoietic malignancy, NOS</term>
				</ns2:diseaseTerm>
				<leadDisease>false</leadDisease>
			</ns2:ctepStudyDisease>
			<ns2:ctepStudyDisease>
				<ns2:diseaseTerm>
					<term>Solid tumor, NOS</term>
				</ns2:diseaseTerm>
				<leadDisease>false</leadDisease>
			</ns2:ctepStudyDisease>
		</ctepStudyDiseases>
		<evaluationPeriods>
			<ns2:evaluationPeriod>
				<name>Baseline</name>
				<epochOrder>0</epochOrder>
			</ns2:evaluationPeriod>
			<ns2:evaluationPeriod>
				<name>Treatment</name>
				<epochOrder>1</epochOrder>
			</ns2:evaluationPeriod>
			<ns2:evaluationPeriod>
				<name>Post-treatment</name>
				<epochOrder>2</epochOrder>
			</ns2:evaluationPeriod>
		</evaluationPeriods>
		<expectedAECtcTerms>
			<ns2:expectedAECtcTerm>
				<ctepCode>10038062</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065850</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065891</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065894</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065892</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10034474</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10035742</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10012727</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065734</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10030223</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10014810</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10023889</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10056848</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065717</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10036787</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10014817</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065714</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065708</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065721</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065726</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065733</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065880</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10028130</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065881</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10063190</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065710</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065715</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065900</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10010774</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10002646</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10020582</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10001675</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10001551</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10003481</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10001760</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10016256</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10013963</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10015218</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10012373</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10001497</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10022437</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10013573</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10010300</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10011368</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10037032</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10019211</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10013963</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10016256</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10028813</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10047700</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10028411</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10020582</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10007196</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10043607</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10022763</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10008479</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10020772</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10021097</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10037853</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10009887</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065723</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10010000</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10013830</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065730</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065732</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065707</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10041101</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10021328</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10008531</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10019211</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10016256</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10002156</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10009995</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10013828</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065728</ctepCode>
			</ns2:expectedAECtcTerm>
			<ns2:expectedAECtcTerm>
				<ctepCode>10065719</ctepCode>
			</ns2:expectedAECtcTerm>
		</expectedAECtcTerms>
	</ns2:study>
</ns2:studies>